Results 61 to 70 of about 359 (75)

Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria

Expert Review of Clinical Pharmacology, 2021
Janneke Langendonk, Debby Wensink, Margreet Wagenmakers   +2 more
exaly  

Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide

Photochemical and Photobiological Sciences, 2021
Mariachiara Arisi, Mariateresa Rossi, Arisi Mariachiara   +2 more
exaly  

Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria

Expert Opinion on Investigational Drugs, 2010
Elisabeth Minder
exaly  

Afamelanotide for Erythropoietic Protoporphyria

New England Journal of Medicine, 2015
Robert Desnick, John Wilson
exaly  

Advances in the management of erythropoietic protoporphyria – role of afamelanotide

The Application of Clinical Genetics, 2016

exaly  

Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice

JAMA Dermatology, 2020
John Wilson, Jasmin Barman-Aksözen, Janneke Langendonk   +2 more
exaly  

The Efficacy of Afamelanotide and Narrowband UV-B Phototherapy for Repigmentation of Vitiligo

JAMA Dermatology, 2013
Henry Wan-Peng Lim, Iltefat Hamzavi
exaly  

Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications

Journal of Drugs in Dermatology, 2021
exaly  

Afamelanotide and Narrowband UV-B Phototherapy for the Treatment of Vitiligo

JAMA Dermatology, 2015
Henry Wan-Peng Lim, Iltefat Hamzavi
exaly